Moreover, because the activation of IGFs/IGF-1R signaling results in the bypass pathway, the combination of IGF-1R mAbs/TKIs and other RTKs as anti-tumor agents is considered to a more effective strategy in cancer therapy. This evidence concerns the gene IGF1R and cancer.